Figure 1.

Analysis of rRp450 efficacy in sarcoma models. (a) Tumor cells were infected with rRp450 at the indicated MOI and harvested for HSV titer as determined by standard plaque assay at 1, 24, 48, and 72 hours post-infection (n = 4). Error bars represent SEM. (b) A673 cells were infected at the indicated MOI and cell viability was measured on days 2, 4, and 6 by MTT assay (n = 4). Error bars represent SD. (c) Mice bearing A673 tumors received two intratumoral injections of rRp450 at 1 × 10⁷ pfu or PBS control, on days 0 and 2, and then followed for tumor growth (n = 7). (d) Mice bearing 143.98.2 tumors received two intratumoral injections of rRp450 at 1 × 10⁷ pfu or PBS as a control on days 0 and 2, and were followed for tumor growth (n = 5–10). CR, complete response; ITu, intratumoral; MOI, multiplicity of infection; oHSV, oncolytic herpes simplex virus; PBS, phosphate-buffered saline; pfu, plaque-forming unit; PD, progressive disease; PR, partial response; SD, stable disease.